Canada markets open in 6 hours 46 minutes

Ionis Pharmaceuticals, Inc. (IONS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
42.27+0.52 (+1.25%)
At close: 04:00PM EDT
40.80 -1.47 (-3.48%)
After hours: 06:42PM EDT

Ionis Pharmaceuticals, Inc.

2855 Gazelle Court
Carlsbad, CA 92010
United States
760 931 9200
https://www.ionispharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees660

Key Executives

NameTitlePayExercisedYear Born
Dr. Brett P. Monia Ph.D.Founder, CEO & Director1.32MN/A1961
Ms. Elizabeth L. HougenExec. VP of Fin. & CFO869.38kN/A1962
Ms. Onaiza Cadoret-ManierExec. VP, Chief Global Product Strategy & Operations Officer755.52kN/A1965
Mr. Patrick R. O'Neil Esq.Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec.815.69kN/A1974
Dr. Stanley T. CrookeScientific Advisor1.64MN/A1945
Ms. B. Lynne Parshall Esq., J.D.Sr. Strategic Advisor & Director701.77kN/A1954
Dr. Eric E. Swayze Ph.D.Exec. VP of Research739.3kN/A1966
Mr. Joel EdwardsVP of Corp. OperationsN/AN/A1961
Mr. Darren GonzalesChief Accounting Officer & Sr. VPN/AN/AN/A
Dr. C. Frank BennettExec. VP & Chief Scientific OfficerN/AN/A1957
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Corporate Governance

Ionis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2022 is 3. The pillar scores are Audit: 6; Board: 2; Shareholder Rights: 5; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.